NCYT:LON
Novacyt SA
GBX 39.50
arrow_downward
-0.25%(-0.100) 1 天
10月16日, GMT+1 16:35:25 · GBX
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 NCYT 生成关键数据洞见…
开盘价
GBX 39.60
最高价
GBX 39.68
最低价
GBX 39.20
市值
3240.94万
平均成交量
10.26万
成交量
1.22万
52 周最高价
GBX 86.00
52 周最低价
GBX 26.60
流通股数
3766.43万
员工人数
228
开盘价
GBX 39.60
最高价
GBX 39.68
最低价
GBX 39.20
市值
3240.94万
平均成交量
10.26万
成交量
1.22万
52 周最高价
GBX 86.00
52 周最低价
GBX 26.60
流通股数
3766.43万
员工人数
228
新闻报道
来自网络来源和新闻合作伙伴
Traders Union
·
1天前
投资者撤离科技股，标普500指数期货上涨
VT Markets
·
1天前
标普500指数回升：医疗保健板块上涨抵消AI概念股抛售压力
资料
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA简介